Henry Andoh, MD
Infectious Disease · Munster, INNPI 1578637245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $324, 2.1 times the $155 reported in 2019.
Across 34 payments — averaging $33.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$223
- AbbVie$188
- Abiomed$150
- Viiv Healthcare Company$101
- Organogenesis Inc.$101
- AstraZeneca$95
- plus $288 from 6 others
What the payments were for
- Food & beverage$1,147100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $223 |
| AbbVie | 7 | $188 |
| Abiomed | 1 | $150 |
| Viiv Healthcare Company | 5 | $101 |
| Organogenesis Inc. | 1 | $101 |
| AstraZeneca | 1 | $95 |
| EKOS Corporation | 1 | $93 |
| Bayer | 1 | $89 |
| Mayne Pharma Commercial LLC | 2 | $43 |
| Vyera Pharmaceuticals, LLC | 2 | $28 |
| Pfizer | 1 | $21 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$150
How this compares
$1,147 in reported general payments places this provider in the 70th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 34 | $139,455 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 15 | $68,700 |
| Aztreonam | 11 | $8,341 |
| Daptomycin | 25 | $4,805 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 14 | $4,482 |
| Linezolid | 17 | $2,680 |
| Vancomycin Hcl | 17 | $2,124 |
| CefuroximeCefuroxime Axetil | 24 | $1,524 |
| Cefepime Hcl | 12 | $1,487 |
| Doxycycline Hyclate | 24 | $1,081 |
| Levofloxacin | 54 | $295 |
| Dapsone | 11 | $291 |
| Ciprofloxacin Hcl | 38 | $217 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $197 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $136 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Munster
- Ricardo QuezadaMunster$1K
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
- Markian BochanCarmel$54K
- Samir GuptaIndianapolis$53K
- Erica Kaufman WestDyer$48K
- Tracey IkerdCarmel$39K
- Darron BrownIndianapolis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.